Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.

IF 4 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Expert Opinion on Biological Therapy Pub Date : 2025-09-01 Epub Date: 2025-09-16 DOI:10.1080/14712598.2025.2555830

Danilo Rocco, Luigi Della Gravara, Cristina Boccia, Cesare Gridelli

{"title":"Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.","authors":"Danilo Rocco, Luigi Della Gravara, Cristina Boccia, Cesare Gridelli","doi":"10.1080/14712598.2025.2555830","DOIUrl":null,"url":null,"abstract":"Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunotherapy in the form of Immune Checkpoint Inhibitors (ICIs) has revolutionized oncology treatment strategies and several ICIs have been investigated for the neoadjuvant treatment of NSCLC, both in monotherapy and in combination with other ICIs or chemotherapy.Areas covered: Therefore, this paper aims to review the currently available data supporting the role of immunotherapy in the neoadjuvant setting, as well as to discuss the challenges associated with it. We undertook a comprehensive literature search of PubMed, Embase, Cochrane Library, of abstracts and posters from annual meetings of American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and American Association for Cancer Research (AACR) up until November 2024.Expert opinion: We believe that in the near future ICI plus chemotherapy combinations will represent the new recommended standard of care in the neoadjuvant/perioperative setting. We look forward to the full results coming from the ongoing randomized phase III trials, that will help us guide our choice in terms of patient selection, regimen of choice, and response assessment.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"979-988"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2025.2555830","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: From the 1960s and up until 2021, neoadjuvant chemotherapy has represented the standard of care for potentially resectable stage III (N2) Non-Small Cell Lung Cancer (NSCLC). However, in recent years, immunotherapy in the form of Immune Checkpoint Inhibitors (ICIs) has revolutionized oncology treatment strategies and several ICIs have been investigated for the neoadjuvant treatment of NSCLC, both in monotherapy and in combination with other ICIs or chemotherapy.

Areas covered: Therefore, this paper aims to review the currently available data supporting the role of immunotherapy in the neoadjuvant setting, as well as to discuss the challenges associated with it. We undertook a comprehensive literature search of PubMed, Embase, Cochrane Library, of abstracts and posters from annual meetings of American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and American Association for Cancer Research (AACR) up until November 2024.

Expert opinion: We believe that in the near future ICI plus chemotherapy combinations will represent the new recommended standard of care in the neoadjuvant/perioperative setting. We look forward to the full results coming from the ongoing randomized phase III trials, that will help us guide our choice in terms of patient selection, regimen of choice, and response assessment.

查看原文本刊更多论文

非小细胞肺癌的新辅助治疗：单克隆抗体的使用和影响的综述。

从20世纪60年代到2021年，新辅助化疗一直是潜在可切除的III期（N2）非小细胞肺癌（NSCLC）的标准治疗方法。然而，近年来，免疫检查点抑制剂（ICIs）形式的免疫治疗已经彻底改变了肿瘤治疗策略，并且已经研究了几种ICIs用于非小细胞肺癌的新辅助治疗，无论是单药治疗还是与其他ICIs或化疗联合治疗。涵盖领域：因此，本文旨在回顾目前可用的支持免疫治疗在新辅助治疗中的作用的数据，并讨论与之相关的挑战。我们在PubMed， Embase， Cochrane图书馆进行了全面的文献检索，检索了截至2024年11月美国临床肿瘤学会（ASCO），欧洲肿瘤医学学会（ESMO）和美国癌症研究协会（AACR）年会的摘要和海报。专家意见：我们相信在不久的将来，ICI +化疗组合将代表新辅助/围手术期环境下新的推荐护理标准。我们期待着正在进行的随机III期试验的完整结果，这将帮助我们在患者选择、方案选择和反应评估方面指导我们的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.